164 related articles for article (PubMed ID: 36294544)
1. Prospective Evaluation of Different Methods for Volumetric Analysis on [
Lopci E; Elia C; Catalfamo B; Burnelli R; De Re V; Mussolin L; Piccardo A; Cistaro A; Borsatti E; Zucchetta P; Bianchi M; Buffardi S; Farruggia P; Garaventa A; Sala A; Vinti L; Mauz-Koerholz C; Mascarin M
J Clin Med; 2022 Oct; 11(20):. PubMed ID: 36294544
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of baseline and interim [
Yadgarov MY; Dunaykin MM; Shestopalov GI; Kailash C; Kireeva ED; Myakova NV; Likar YN
Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):1955-1964. PubMed ID: 38351389
[TBL] [Abstract][Full Text] [Related]
3. Prognostic utility of serial
Fernando S; Lin M; Pham TT; Chong S; Ip E; Wong K; Chua W; Ng W; Lin P; Lim S
Br J Radiol; 2020 Jan; 93(1105):20190455. PubMed ID: 31617737
[TBL] [Abstract][Full Text] [Related]
4. Additional value of volumetric and texture analysis on FDG PET assessment in paediatric Hodgkin lymphoma: an Italian multicentric study protocol.
Lopci E; Burnelli R; Elia C; Piccardo A; Castello A; Borsatti E; Zucchetta P; Cistaro A; Mascarin M;
BMJ Open; 2021 Mar; 11(3):e041252. PubMed ID: 33782017
[TBL] [Abstract][Full Text] [Related]
5. Pretherapeutic FDG-PET total metabolic tumor volume predicts response to induction therapy in pediatric Hodgkin's lymphoma.
Rogasch JMM; Hundsdoerfer P; Hofheinz F; Wedel F; Schatka I; Amthauer H; Furth C
BMC Cancer; 2018 May; 18(1):521. PubMed ID: 29724189
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of Combined Metabolic-Volumetric Indices of (18)F-FDG PET/CT for the Early Prediction of Neoadjuvant Chemotherapy Outcomes in Breast Cancer.
Im HJ; Kim YK; Kim YI; Lee JJ; Lee WW; Kim SE
Nucl Med Mol Imaging; 2013 Mar; 47(1):36-43. PubMed ID: 24895506
[TBL] [Abstract][Full Text] [Related]
7. The role of
Rufini V; Collarino A; Calcagni ML; Meduri GM; Fuoco V; Pasciuto T; Testa AC; Ferrandina G; Gambacorta MA; Campitelli M; Gui B; Zannoni G; Manfredi R; Scambia G; Giordano A
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1228-1238. PubMed ID: 31414206
[TBL] [Abstract][Full Text] [Related]
8. FDG-PET Response Prediction in Pediatric Hodgkin's Lymphoma: Impact of Metabolically Defined Tumor Volumes and Individualized SUV Measurements on the Positive Predictive Value.
Hussien AE; Furth C; Schönberger S; Hundsdoerfer P; Steffen IG; Amthauer H; Müller HW; Hautzel H
Cancers (Basel); 2015 Jan; 7(1):287-304. PubMed ID: 25635760
[TBL] [Abstract][Full Text] [Related]
9. Consistency of metabolic tumor volume of non-small-cell lung cancer primary tumor measured using 18F-FDG PET/CT at two different tracer uptake times.
Liu H; Chen P; Wroblewski K; Hou P; Zhang CP; Jiang Y; Pu Y
Nucl Med Commun; 2016 Jan; 37(1):50-6. PubMed ID: 26426969
[TBL] [Abstract][Full Text] [Related]
10. Reproducibility of Standardized Uptake Values Including Volume Metrics Between TOF-PET-MR and TOF-PET-CT.
Tanaka A; Sekine T; Ter Voert EEGW; Zeimpekis KG; Delso G; de Galiza Barbosa F; Warnock G; Kumita SI; Veit Haibach P; Huellner M
Front Med (Lausanne); 2022; 9():796085. PubMed ID: 35308500
[TBL] [Abstract][Full Text] [Related]
11. Volume-based parameters on FDG PET may predict the proliferative potential of soft-tissue sarcomas.
Kitao T; Shiga T; Hirata K; Sekizawa M; Takei T; Yamashiro K; Tamaki N
Ann Nucl Med; 2019 Jan; 33(1):22-31. PubMed ID: 30196378
[TBL] [Abstract][Full Text] [Related]
12. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.
Salavati A; Duan F; Snyder BS; Wei B; Houshmand S; Khiewvan B; Opanowski A; Simone CB; Siegel BA; Machtay M; Alavi A
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1969-1983. PubMed ID: 28689281
[TBL] [Abstract][Full Text] [Related]
13. The Evaluation of Preoperative
Vural Topuz Ö; Aksu A; Erinç SR; Tokgözoğlu N; Tamam MÖ
Mol Imaging Radionucl Ther; 2022 Feb; 31(1):16-22. PubMed ID: 35114747
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of standardized uptake value on F18-FDG PET/CT in patients with extranodal nasal type NK/T cell lymphoma: A multicenter, retrospective analysis.
Pak K; Kim BS; Kim K; Kim IJ; Jun S; Jeong YJ; Shim HK; Kim SD; Cho KS
Am J Otolaryngol; 2018; 39(1):1-5. PubMed ID: 29056243
[TBL] [Abstract][Full Text] [Related]
15. Pre- and per-treatment 18F-FDG PET/CT parameters to predict recurrence and survival in cervical cancer.
Leseur J; Roman-Jimenez G; Devillers A; Ospina-Arango JD; Williaume D; Castelli J; Terve P; Lavoue V; Garin E; Lejeune F; Acosta O; De Crevoisier R
Radiother Oncol; 2016 Sep; 120(3):512-518. PubMed ID: 27569847
[TBL] [Abstract][Full Text] [Related]
16. Correlation of
Mayoral M; Paredes P; Saco A; Fusté P; Perlaza P; Tapias A; Fernandez-Martinez A; Vidal L; Ordi J; Pavia J; Martinez-Roman S; Lomeña F
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):80-86. PubMed ID: 28869177
[TBL] [Abstract][Full Text] [Related]
17. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma.
Albano D; Bosio G; Pagani C; Re A; Tucci A; Giubbini R; Bertagna F
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):87-96. PubMed ID: 30276438
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial.
van Heek L; Stuka C; Kaul H; Müller H; Mettler J; Hitz F; Baues C; Fuchs M; Borchmann P; Engert A; Dietlein M; Voltin CA; Kobe C
BMC Cancer; 2022 Jun; 22(1):672. PubMed ID: 35717166
[TBL] [Abstract][Full Text] [Related]
19. 18F-FDG PET/CT of Non-Small Cell Lung Carcinoma Under Neoadjuvant Chemotherapy: Background-Based Adaptive-Volume Metrics Outperform TLG and MTV in Predicting Histopathologic Response.
Burger IA; Casanova R; Steiger S; Husmann L; Stolzmann P; Huellner MW; Curioni A; Hillinger S; Schmidtlein CR; Soltermann A
J Nucl Med; 2016 Jun; 57(6):849-54. PubMed ID: 26823566
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
